Evidence map›Paper›PMID 39812918›Full record

Trial reportAnnals of surgical oncology2025

Phase I/II Study of Neoadjuvant Chemoradiotherapy Consisting of S-1 and Cisplatin for Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer (OGSG1205).

Masayuki Shinkai, Motohiro Imano, Masaki Yokokawa, Ryo Tanaka, Jin Matsuyama, Toshio Shimokawa, Hisato Kawakami, Taroh Satoh, Takushi Yasuda, Hiroshi Furukawa

Abstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Masayuki ShinkaiDepartment of Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka, Japan.
Motohiro ImanoDepartment of Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka, Japan. imano@med.kindai.ac.jp.
Masaki YokokawaDepartment of Radiation Oncology, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka, Japan.
Ryo TanakaDepartment of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Jin MatsuyamaDepartment of Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Osaka, Japan.
Toshio ShimokawaClinical Study Support Center, Wakayama Medical University, Wakayama, Japan.
Hisato KawakamiDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka, Japan.
Taroh SatohCenter for Cancer Genomics and Precision Medicine, Osaka University Hospital, Suita, Osaka, Japan.
Takushi YasudaDepartment of Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka, Japan.
Hiroshi FurukawaDepartment of Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo improve the prognosis of clinically resectable type 4 or large type 3 gastric cancer (GC), we performed a phase I/II study of neoadjuvant-radiotherapy combined with S-1 plus cisplatin. PATIENTS AND

methodsPhase I, with a standard 3 + 3 dose-escalation design, was performed to define the recommended phase II dose. Efficacy and safety were evaluated in phase II. The three dose levels were as follows: level 0, S-1 60 mg/m

resultsA total of six patients were enrolled in the phase I study. Dose-limiting toxicity was observed at level 2; level 1 was established as the recommended phase II dose. In phase II, 20 patients were enrolled from November 2012 to April 2018. Grade 3/4 leukopenia and nonhematologic adverse events occurred in 35% and 5% of the patients, respectively. In total, 19 patients underwent the protocol surgery; 2 (10.5%) achieved a pathological complete response. There were no treatment-related deaths; 3- and 5-year overall survival rates were 70.0 and 50.0%, respectively.

conclusionsNeoadjuvant chemoradiotherapy with S-1 plus cisplatin is a safe and promising treatment for clinically resectable type 4 or large type 3 GC.

Indexed as

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyStomach NeoplasmsAdultAgedChemoradiotherapyCisplatinDrug CombinationsFemaleFollow-Up StudiesHumansMaleMiddle AgedOxonic AcidPrognosisCisplatinDrug CombinationsOxonic AcidS 1 (combination)TegafurChemoradiotherapyCisplatinGastric cancerLarge type 3Phase I/IIS-1Type 4

Identifiers

PMID39812918
PMCPMC11882648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.